证券日报网讯2月9日，红日药业（300026）在互动平台回答投资者提问时表示，公司对中药配方颗粒等 核心主业的产能与供应链投入，是基于国家行业标准切换、市场长期需求及公司全国布局的战略性投 资，旨在巩固并提升公司在核心业务领域的竞争优势与市场占有率，为公司提供持续稳定的盈利基础。 公司对外投资及内部资金运作均严格遵守国家法律法规及上市公司监管要求，履行了必要的审批程序及 信息披露义务，不存在任何非合规资金运作的情形。公司高度重视投资者的诉求，公司的信息披露工作 是基于公平信息披露原则的合规操作。针对所涉事项目若尚未达到法定信息披露标准，也未对公司生产 经营，财务状况产生重大影响，公司无法在互动易平台进行答复。若在平台对未达披露标准的事项进行 证实或辟谣，将造成信息不对称，损害中小投资者的公平知情权，违背信息披露的核心原则。公司始终 对相关事项进展保持密切跟踪，若后续事项达到《上市公司信息披露管理办法》规定的重大事项披露标 准，将第一时间通过巨潮资讯网等指定信息披露渠道发布公告，确保所有投资者同步获取信息。 ...

（文章来源：证券日报） 证券日报网讯 2月9日，红日药业在互动平台回答投资者提问时表示，近三年公司研发投入金额及情况 详见定期报告。 ...

证券日报网讯 2月9日，红日药业在互动平台回答投资者提问时表示，二级市场股价波动受宏观经济、 行业政策、市场情绪及资金偏好等多重复杂因素影响。公司始终以全体股东利益最大化为核心，推进公 司各项业务的开展，聚焦主业提升内生增长力。相关具体措施与成效，可关注定期报告。 （文章来源：证券日报） ...

（记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：超思子公司在印度有开展业务，当前印度尼帕病毒疫 情是否带动公司相关医疗检测设备需求增长？ 红日药业（300026.SZ）2月9日在投资者互动平台表示，印度尼帕病毒对公司整体业绩影响不大，具体 数据请关注定期报告。 ...

证券日报网讯 2月6日，红日药业发布公告称，公司于近日收到国家药品监督管理局下发的药物临床试 验批准通知书（通知书编号：2026LP00325）。根据《中华人民共和国药品管理法》及有关规定，经国 家药监局审查，公司申报的注射用甲磺酸萘莫司他符合药品注册的有关要求，同意本品开展临床试验。 （编辑 王雪儿） ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

证券日报网讯2月6日，红日药业（300026）在互动平台回答投资者提问时表示，互动易平台是上市公司 与投资者交流的平台，对于投资者提问，公司会积极、务实、审慎地回复。对于个别提问中出现的蹭热 点、传播不实信息、灌水式的提问、可能对中小投资者产生误导或可能影响股东利益的提问，公司会谨 慎地甄别和处理。公司也希望广大投资者和公司一起，共同维护互动易平台的严肃性，维护投资者和股 东利益。 ...

注射用甲磺酸萘莫司他用于改善胰腺炎的急性症状；治疗弥散性血管内凝血综合征（DIC）；用于防止 有出血性病变或出血倾向的患者血液体外循环时灌流血液的凝固（血液透析和血浆置换）。同时，注射 用甲磺酸萘莫司他为新型的蛋白酶抑制剂，对胰蛋白酶、补体系统、凝血纤溶系统及血小板凝集，具有 强力且广泛的抑制作用。通过可逆性抑制胰蛋白酶样丝氨酸蛋白酶发挥药理作用。 格隆汇2月6日丨红日药业(300026.SZ)公布，近日收到国家药品监督管理局下发的药物临床试验批准通 知书。根据《中华人民共和国药品管理法》及有关规定，经国家药监局审查，公司申报的注射用甲磺酸 萘莫司他符合药品注册的有关要求，同意本品开展临床试验。 ...

Core Viewpoint - Hongri Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its injectable drug, Nirmatrelvir Mesylate, which is aimed at preventing blood coagulation during extracorporeal circulation [1] Group 1: Drug Approval and Specifications - The drug is classified as a Class 3 chemical drug and is specified in a dosage of 50mg [1] - The approved indication for the drug includes the prevention of blood coagulation during extracorporeal circulation [1] Group 2: Additional Benefits - Nirmatrelvir Mesylate is also noted for its potential to improve symptoms of pancreatitis, indicating its broader therapeutic applications as a novel protease inhibitor [1]

天津红日药业股份有限公司 天津红日药业股份有限公司 关于注射用甲磺酸萘莫司他获得药物临床试验批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）下发的药物临床试验批准通知书（通知书编 号：2026LP00325）。根据《中华人民共和国药品管理法》及有关规定，经国家 药监局审查，公司申报的注射用甲磺酸萘莫司他符合药品注册的有关要求，同意 本品开展临床试验。现将相关情况公告如下： 一、药品基本情况 药品名称：注射用甲磺酸萘莫司他 剂型：注射剂 证券代码：300026 证券简称：红日药业 公告编号：2026-005 注射用甲磺酸萘莫司他用于改善胰腺炎的急性症状；治疗弥散性血管内凝血 综合征（DIC）；用于防止有出血性病变或出血倾向的患者血液体外循环时灌流血 液的凝固（血液透析和血浆置换）。同时，注射用甲磺酸萘莫司他为新型的蛋白 1 规格：50mg 注册分类：化药3类 申请事项：临床试验 持有人：天津红日药业股份有限公司 受理号：CYHL2500211 审批结论 ...